PeptidePedia The community reference

MOTS-c (revision 13)

Old revision·22:48, 2 May 2025·MissedDoseMik

This is an old revision of this page, as it stood at 22:48, 2 May 2025, saved by MissedDoseMik with the summary state which receptor subtype the binding data refers to. It may differ substantially from the current revision, and any error it contains may since have been corrected.
MOTS-cResearch peptide
Full nameMitochondrial open reading frame of the 12S rRNA type-c
Encoded inMitochondrial DNA
Residues16
StatusNot approved; preclinical and early human study
Compound infobox · conventions

MOTS-c is a 16-residue peptide encoded within the mitochondrial genome rather than the nuclear genome, and is one of a small group of mitochondria-derived peptides identified since the 2000s. It is not approved for any indication.[1]

Its proposed physiological role is as a signal from mitochondria to the rest of the cell and to distant tissues, influencing metabolic homeostasis. In rodent work it has been reported to improve insulin sensitivity and to protect against diet-induced obesity, through effects converging on AMP-activated protein kinase.[1]

Human evidence is very limited. Circulating concentrations have been measured and associated with metabolic phenotypes in observational studies, and controlled interventional data are sparse.[2]

Origin and identification

[edit]

The mitochondrial genome was long thought to encode only 13 proteins, all components of the respiratory chain. Short open reading frames within mitochondrial ribosomal RNA genes were subsequently found to encode small peptides, of which humanin was the first and MOTS-c one of the better characterised.[1]

The genomic origin has a practical consequence: mitochondrial DNA is maternally inherited and accumulates variants differently from nuclear DNA, so polymorphism in these peptides follows mitochondrial haplogroup rather than ordinary Mendelian patterns.[2]

Detection and quantification are analytically demanding. Short peptides at low circulating concentration require sensitive and specific methods, and reported concentrations differ between studies using different assays — the same caution that applies to any peptide immunoassay. See Proglucagon for a worked example of the problem.[2]

Reported effects

[edit]

In rodents, administration has been reported to improve insulin sensitivity, increase glucose disposal, and attenuate diet-induced obesity, with AMP-activated protein kinase activation the proposed common mechanism.[1]

In humans, exercise increases circulating MOTS-c, and lower concentrations have been associated with obesity and insulin resistance in cross-sectional studies. Association of that kind cannot establish direction: lower concentrations may contribute to the phenotype or result from it.[2]

See also

References

  1. ^ a b c d Lee C, Zeng J, Drew BG, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism 21(3):443–454 (2015). PMID 25738459.
  2. ^ a b c d Kim KH, Son JM, Benayoun BA, Lee C. "The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress." Cell Metabolism 28(3):516–524 (2018). PMID 29983246.